JP2011507845A5 - - Google Patents

Download PDF

Info

Publication number
JP2011507845A5
JP2011507845A5 JP2010539469A JP2010539469A JP2011507845A5 JP 2011507845 A5 JP2011507845 A5 JP 2011507845A5 JP 2010539469 A JP2010539469 A JP 2010539469A JP 2010539469 A JP2010539469 A JP 2010539469A JP 2011507845 A5 JP2011507845 A5 JP 2011507845A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
surgical treatment
brimonidine
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010539469A
Other languages
English (en)
Japanese (ja)
Other versions
JP5580210B2 (ja
JP2011507845A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/013797 external-priority patent/WO2009082452A1/en
Publication of JP2011507845A publication Critical patent/JP2011507845A/ja
Publication of JP2011507845A5 publication Critical patent/JP2011507845A5/ja
Application granted granted Critical
Publication of JP5580210B2 publication Critical patent/JP5580210B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010539469A 2007-12-21 2008-12-17 手術前治療 Expired - Fee Related JP5580210B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1591207P 2007-12-21 2007-12-21
US61/015,912 2007-12-21
PCT/US2008/013797 WO2009082452A1 (en) 2007-12-21 2008-12-17 Pre-surgical treatment

Publications (3)

Publication Number Publication Date
JP2011507845A JP2011507845A (ja) 2011-03-10
JP2011507845A5 true JP2011507845A5 (OSRAM) 2012-02-16
JP5580210B2 JP5580210B2 (ja) 2014-08-27

Family

ID=40801507

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010539469A Expired - Fee Related JP5580210B2 (ja) 2007-12-21 2008-12-17 手術前治療

Country Status (10)

Country Link
US (1) US20110224215A1 (OSRAM)
EP (1) EP2230910A4 (OSRAM)
JP (1) JP5580210B2 (OSRAM)
KR (1) KR20100099191A (OSRAM)
CN (1) CN101902913B (OSRAM)
AU (1) AU2008341112B2 (OSRAM)
BR (1) BRPI0822095A2 (OSRAM)
CA (1) CA2709199A1 (OSRAM)
NZ (1) NZ586302A (OSRAM)
WO (1) WO2009082452A1 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
BRPI0819075A2 (pt) 2007-11-16 2014-10-07 Vicept Therapeutics Inc Método para tratar púrpura em um indivíduo e método para diminuir a púrpura em um indivíduo antes de um procedimento cirúrgico
US9050246B2 (en) * 2009-05-29 2015-06-09 Galderma Research & Development Injectable combination of adrenergic receptor agonists with fillers, for decreasing skin reactions due to injection
BR112012024289A2 (pt) * 2010-03-26 2017-07-18 Galderma Res & Dev "método para fornecer um tratamento seguro e efetivo do eritema e composição de gel tópica"
MX2012010823A (es) * 2010-03-26 2012-10-10 Galderma Res & Dev Metodos y composiciones mejoradas para tratamiento seguro y efectivo de telangiectasia.
FR2966365B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel topique
EP2629757A2 (en) * 2010-10-21 2013-08-28 Galderma S.A. Brimonidine gel compositions and methods of use
FR2966366B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel de brimonidine
CA2814975A1 (en) * 2010-10-21 2012-04-26 Galderma S.A. Topical gel composition
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
FR2977493B1 (fr) * 2011-07-05 2014-02-14 Galderma Res & Dev Nouvelle composition anesthesique stable pour la reduction des reactions cutanees
US9744168B2 (en) 2011-10-19 2017-08-29 Galderma Laboratories, Inc. Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors
JP6339364B2 (ja) * 2013-12-27 2018-06-06 カズマパートナーズ株式会社 無定形ブリモニジン酒石酸塩及びその製造方法
EP3700539A4 (en) * 2017-10-23 2021-07-14 Microcures, Inc. METHOD OF IMPROVING THE RECOVERY OF A SKIN TREATED WITH A COSMETIC LASER

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92351A (en) 1988-11-29 1994-02-27 Allergan Inc Irvine Aqueous opthalmic solutions containing stabilized chlorine dioxide and an inorganic salt
US5736165A (en) 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
CA2154979A1 (en) * 1995-07-28 1997-01-29 Kenneth T. Armstrong Topical phenylephrine preparation
US7973068B2 (en) * 1998-10-20 2011-07-05 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
US6294553B1 (en) * 2000-02-15 2001-09-25 Allergan Sales, Inc. Method for treating ocular pain
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
BRPI0819075A2 (pt) * 2007-11-16 2014-10-07 Vicept Therapeutics Inc Método para tratar púrpura em um indivíduo e método para diminuir a púrpura em um indivíduo antes de um procedimento cirúrgico

Similar Documents

Publication Publication Date Title
JP2011507845A5 (OSRAM)
RU2707254C1 (ru) Водный фармацевтический препарат и способ лечения хронической язвы
Barret et al. Accelerated re-epithelialization of partial-thickness skin wounds by a topical betulin gel: Results of a randomized phase III clinical trials program
CN104307032B (zh) 一种止痛、抗菌、止血并促进伤口愈合的液体敷料
JP2019513136A5 (OSRAM)
WO2017011982A1 (zh) 贻贝粘蛋白产品及其抑制皮肤炎症的应用
US20140044667A1 (en) Healing composition for topical application
JP2017514866A5 (OSRAM)
Abboud et al. Do silver-based wound dressings reduce pain? A prospective study and review of the literature
WO2014210308A1 (en) Method of reducing scarring
CN103143052A (zh) 医用胶原敷料及其制备方法和用途
RU2015146679A (ru) Тетрапептиды, полученные из с-х-с-хемокинов человека, подходящие для лечения различных состояний кожи
RU2009107068A (ru) Применение пропиленгликоля при лечении связанных с воспалением местных нарушений или заболеваний и ран
RU2015148636A (ru) Модуляция активности гепарин-связывающего эпидермального фактора роста для заживления барабанной перепонки
RU2423118C1 (ru) Способ лечения трофических язв
Feldstein et al. Chemical burn from vinegar following an internet-based protocol for self-removal of nevi
CN104490760B (zh) 辣椒碱‑胶原蛋白海绵的制备方法及其应用
JP5796728B1 (ja) 創傷治癒を促進し生体諸臓器の被覆（コーチング）及び庇護を目的とした生体皮膜剤。
Karri et al. Understanding the implications of pharmaceutical excipients and additives in the treatment of diabetic foot ulcers
TWI610674B (zh) 一種用於促進傷口癒合或預防、減少傷口疤痕生成的醫藥組合物
US20150086529A1 (en) Therapeutic Burn Gel
KR101820519B1 (ko) 설글리코타이드의 피부 상처 치유 촉진 용도, 및 이를 포함하는 외용제 조성물
CN106880765A (zh) 一种外伤动物模型的构建及促进伤口愈合的方法
CN103120723B (zh) 用于治疗烫伤、烧伤和刀伤的中药组合物及其制备方法
Kumar et al. Innovations in Advanced Wound Care from India